What’s the current market cap for Genmab A/S stock?

Genmab A/S (GMAB) has a market cap of €13bn as of June 18, 2026.

What is the P/E ratio for Genmab A/S stock?

The price to earnings (P/E) ratio for Genmab A/S (GMAB) stock is 19.27 as of June 18, 2026.

Does Genmab A/S stock pay dividends?

No, Genmab A/S (GMAB) stock does not pay dividends to its shareholders as of June 18, 2026.

When is the next Genmab A/S dividend payment date?

Genmab A/S (GMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Genmab A/S?

Genmab A/S (GMAB) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Genmab A/S stock | €GMAB Share Price

05:30

09:10

12:45

16:25

20:00

About Genmab A/S

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.

Ticker

€GMAB

Sector

Health

Primary listing

XGAT

Employees

3,088

Headquarters

Copenhagen, Denmark

Website

www.genmab.com

Genmab A/S Metrics

BasicAdvanced

€13bn

19.27

€11.38

0.69

Bulls say / Bears say

Royalty revenue in Q1 2026 rose 26% year-over-year to $742 million, driven by strong DARZALEX and Kesimpta sales, underscoring Genmab’s robust collaboration income streams (Genmab Q1 2026 Interim Report).

DARZALEX net sales increased 22% year-over-year to $3.964 billion in Q1 2026, reinforcing Genmab’s core royalty engine and enhancing cash flow predictability (Genmab Q1 2026 Interim Report).

On December 12, 2025, Genmab completed its $6.9 billion acquisition of Merus, adding the late-stage bispecific antibody petosemtamab to its proprietary pipeline and bolstering long-term growth prospects (Genmab Q1 2026 Interim Report).

Merus acquisition financing led to $108 million of interest and amortisation expenses in Q1 2026, eroding net profit and pressuring cash flow (Genmab Q1 2026 Interim Report).

Operating expenses, excluding acquisition and integration charges, jumped 25% year-over-year to €606 million in Q1 2026, driven by accelerated R&D and commercialization investments for Rina-S and petosemtamab, which may strain margins if pipeline milestones slip (Genmab Q1 2026 Interim Report).

Genmab’s Japanese subsidiaries face multiple Chugai patent infringement lawsuits over Epcoritamab (EPKINLY), posing potential delays to commercialization and significant legal liabilities (Genmab Q1 2026 Interim Report).

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Bulls say / Bears say

DARZALEX net sales increased 22% year-over-year to $3.964 billion in Q1 2026, reinforcing Genmab’s core royalty engine and enhancing cash flow predictability (Genmab Q1 2026 Interim Report).

Merus acquisition financing led to $108 million of interest and amortisation expenses in Q1 2026, eroding net profit and pressuring cash flow (Genmab Q1 2026 Interim Report).

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

About Genmab A/S

Ticker

Primary listing

Employees

Headquarters

Genmab A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €GMAB

Lightyear

Legal

Work with us

Bulls say / Bears say

Genmab A/S/€GMAB

About Genmab A/S

Ticker

Primary listing

Employees

Headquarters

Genmab A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Genmab A/S stock?

What is the P/E ratio for Genmab A/S stock?

Does Genmab A/S stock pay dividends?

When is the next Genmab A/S dividend payment date?

What is the beta indicator for Genmab A/S?

Bulls say / Bears say